Trial · NCT00724893
Outcomes52
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 52
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Achieving Viral Response at Any Evaluation Point (Stage 1) | Up to 72 weeks | All participants who took at least one dose of study medication (ITT Population) | participants | NUMBER |
| PRIMARY | Number of Participants Achieving Viral Response at 12 Weeks After EOT (Stage 1) | Up to 62 weeks | All participants who took at least one dose of study medication (ITT population) | Participants | NUMBER |
| PRIMARY | Number of Participants Achieving Sustained Viral Response (SVR) (Stage 1) | Up to 72 weeks | All participants who took at least one dose of study medication (ITT population) | Participants | NUMBER |
| PRIMARY | Number of Participants Achieving SVR (Stage 2) | Up to 72 weeks | All participants who took at least one dose of study medication (ITT Population) | participants | NUMBER |
| SECONDARY | Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2) | Up to 48 weeks | All participants who took at least one dose of study medication (ITT Population) | participants | NUMBER |
| SECONDARY | Number of Participants Achieving Viral Response at Any Evaluation Point, Excluding Participants Who Discontinued Treatment Prior to Early Virologic Response (EVR) Evaluation (Stage 1) | Up to 72 weeks | Participants in the ITT population with EVR evaluation at Treatment Week 12 | Participants | NUMBER |
| SECONDARY | Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1) | Up to 62 weeks | Participants in the ITT population with EVR evaluation at Treatment Week 12 | Participants | NUMBER |
| SECONDARY | Number of Participants Achieving SVR, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1) | Up to 72 weeks | Participants in the ITT population with EVR evaluation at Treatment Week 12 | Participants | NUMBER |
| SECONDARY | The Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1) | Up to 62 weeks | Participants in the ITT population with EVR evaluation at Treatment Week 12 and no missing data | Participants | NUMBER |
| SECONDARY | The Number of Participants Achieving SVR Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1) | Up to 72 weeks | Participants in the ITT population with EVR evaluation at Treatment Week 12 and no missing data | participants | NUMBER |
| SECONDARY | The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1) | Up to 62 weeks | All participants who took at least one dose of study medication (ITT population). | Participants | NUMBER |
| SECONDARY | The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Liver Fibrosis Stage (Stage 1) | Up to 62 weeks | All participants who took at least one dose of study medication (ITT population) | Participants | NUMBER |
| SECONDARY | Number of Participants Achieving SVR by Liver Fibrosis Stage (Stage 1) | Up to 72 weeks | All participants who took at least one dose of study medication (ITT Population) | participants | NUMBER |
| SECONDARY | Number of Participants Achieving SVR by Chronic HCV Genotype (Stage 1) | Up to 72 weeks | All participants who took at least one dose of study medication (ITT Population) | participants | NUMBER |
| SECONDARY | Number of Participants Achieving SVR by Viral Load (Stage 1) | Up to 72 weeks | All participants who took at least one dose of study medication (ITT Population) | participants | NUMBER |
| SECONDARY | Number of Participants Achieving SVR by Weight (Stage 1) | Up to 72 weeks | All participants who took at least one dose of study medication (ITT Population) | participants | NUMBER |
| SECONDARY | Number of Participants Achieving SVR by Chronic HCV Genotype + Liver Fibrosis Stage (Stage 1) | Up to 72 weeks | All participants who took at least one dose of study medication (ITT Population); no participants had Genotype 5 | participants | NUMBER |
| SECONDARY | Number of Participants Achieving SVR by Chronic HCV Genotype + Viral Load (Stage 1) | Up to 72 weeks | All participants who took at least one dose of study medication (ITT Population); no participants had Genotype 5 | participants | NUMBER |
| SECONDARY | Number of Participants Achieving SVR by Weight + Chronic HCV Genotype (Stage 1) | Up to 72 weeks | All participants who took at least one dose of study medication (ITT Population); no participants had Genotype 5 | participants | NUMBER |
| SECONDARY | Number of Participants Achieving EVR (Stage 1) | From Week 10 to Week 14 | The EVR analysis population comprised participants with HCV Genotypes 1, 4, and 6 only, who took at least one dose of study medication. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00724893/outcomes